IRON (Disc Medicine, Inc. Common Stock) Stock Analysis - News
Disc Medicine, Inc. Common Stock (IRON) is a publicly traded Healthcare sector company. As of May 20, 2026, IRON trades at $66.94 with a market cap of $2.55B and a P/E ratio of -11.02. IRON moved +4.67% today. Year to date, IRON is -14.75%; over the trailing twelve months it is +33.85%. Its 52-week range spans $30.82 to $99.50. Analyst consensus is strong buy with an average price target of $98.22. Rallies surfaces IRON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in IRON news today?
Disc Medicine Completes 183-Patient Phase 3 Enrollment, Holds $730M Cash Runway: Disc Medicine completed enrollment of 183 patients in its Phase 3 APOLLO trial of bitopertin for EPP and expects topline data in Q4 2026. The company held $730.2 million in cash and equivalents at quarter end, funding operations into 2029, while net loss widened to $63.5 million.
Disc Medicine Completes 183-Patient Phase 3 Enrollment, Holds $730M Cash Runway: Disc Medicine completed enrollment of 183 patients in its Phase 3 APOLLO trial of bitopertin for EPP and expects topline data in Q4 2026. The company held $730.2 million in cash and equivalents at quarter end, funding operations into 2029, while net loss widened to $63.5 million.
Does Rallies summarize IRON news?
Yes. Rallies summarizes IRON news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is IRON research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IRON. It does not provide personalized investment advice.
